secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001847903-25-000154
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH
--------------------------------------------------------------------------------

- Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.
- Cash and investments $349M as of Sep 30, 2025, expected to fund operations into mid-2027.
- ORX750 Phase 2a showed statistically significant improvements on MWT, ESS, and cataplexy rate across NT1, NT2, and IH at low doses.
- ORX142 Phase 1 demonstrated rapid onset and differentiated PK; patient studies planned for Q1 2026.
- Registrational program for ORX750 expected to start Q1 2026; ORX489 IND-enabling studies ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000154/0001847903-25-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000154/cnta-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001847903-25-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer